nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—Leg edema—Temozolomide—malignant glioma	0.0383	0.0604	CcSEcCtD
Eprosartan—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—COX8A—malignant glioma	0.0227	0.0621	CbGpPWpGaD
Eprosartan—AGTR1—ACE Inhibitor Pathway—BDKRB2—malignant glioma	0.0145	0.0398	CbGpPWpGaD
Eprosartan—Influenza-like symptoms—Temozolomide—malignant glioma	0.0145	0.0228	CcSEcCtD
Eprosartan—Otitis media—Temozolomide—malignant glioma	0.0133	0.0209	CcSEcCtD
Eprosartan—AGTR1—ACE Inhibitor Pathway—KNG1—malignant glioma	0.0132	0.0362	CbGpPWpGaD
Eprosartan—Rigors—Temozolomide—malignant glioma	0.0126	0.0199	CcSEcCtD
Eprosartan—Viral infection—Temozolomide—malignant glioma	0.0114	0.018	CcSEcCtD
Eprosartan—Herpes simplex—Temozolomide—malignant glioma	0.0112	0.0176	CcSEcCtD
Eprosartan—ABCC2—Irinotecan Pathway—BCHE—malignant glioma	0.011	0.0301	CbGpPWpGaD
Eprosartan—Urinary incontinence—Carmustine—malignant glioma	0.0103	0.0162	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—ANGPT2—malignant glioma	0.0101	0.0277	CbGpPWpGaD
Eprosartan—Influenza like illness—Temozolomide—malignant glioma	0.01	0.0158	CcSEcCtD
Eprosartan—Urinary incontinence—Temozolomide—malignant glioma	0.00997	0.0157	CcSEcCtD
Eprosartan—CYP2C9—CYP2E1 reactions—CYP2B6—malignant glioma	0.00956	0.0262	CbGpPWpGaD
Eprosartan—Abnormal vision—Carmustine—malignant glioma	0.00932	0.0147	CcSEcCtD
Eprosartan—ABCC2—Constitutive Androstane Receptor Pathway—CYP2B6—malignant glioma	0.00926	0.0254	CbGpPWpGaD
Eprosartan—Abnormal vision—Temozolomide—malignant glioma	0.00901	0.0142	CcSEcCtD
Eprosartan—Diabetes mellitus—Carmustine—malignant glioma	0.00892	0.014	CcSEcCtD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2B6—malignant glioma	0.00883	0.0242	CbGpPWpGaD
Eprosartan—Swelling—Carmustine—malignant glioma	0.00879	0.0138	CcSEcCtD
Eprosartan—Gastroenteritis—Temozolomide—malignant glioma	0.00846	0.0133	CcSEcCtD
Eprosartan—Vascular purpura—Temozolomide—malignant glioma	0.00838	0.0132	CcSEcCtD
Eprosartan—Hot flush—Temozolomide—malignant glioma	0.00801	0.0126	CcSEcCtD
Eprosartan—Menopausal symptoms—Temozolomide—malignant glioma	0.00794	0.0125	CcSEcCtD
Eprosartan—Hyponatraemia—Carmustine—malignant glioma	0.00779	0.0123	CcSEcCtD
Eprosartan—Purpura—Temozolomide—malignant glioma	0.00778	0.0122	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—GDNF—malignant glioma	0.00766	0.021	CbGpPWpGaD
Eprosartan—Face oedema—Carmustine—malignant glioma	0.00749	0.0118	CcSEcCtD
Eprosartan—Ataxia—Carmustine—malignant glioma	0.00729	0.0115	CcSEcCtD
Eprosartan—Face oedema—Temozolomide—malignant glioma	0.00724	0.0114	CcSEcCtD
Eprosartan—Hypokalaemia—Carmustine—malignant glioma	0.00706	0.0111	CcSEcCtD
Eprosartan—Ataxia—Temozolomide—malignant glioma	0.00705	0.0111	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—IL12A—malignant glioma	0.00701	0.0192	CbGpPWpGaD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—POR—malignant glioma	0.00698	0.0191	CbGpPWpGaD
Eprosartan—Muscular weakness—Carmustine—malignant glioma	0.00684	0.0108	CcSEcCtD
Eprosartan—Hypokalaemia—Temozolomide—malignant glioma	0.00682	0.0107	CcSEcCtD
Eprosartan—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.00675	0.0106	CcSEcCtD
Eprosartan—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—malignant glioma	0.00667	0.0183	CbGpPWpGaD
Eprosartan—Muscular weakness—Temozolomide—malignant glioma	0.00661	0.0104	CcSEcCtD
Eprosartan—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.00661	0.0104	CcSEcCtD
Eprosartan—AGTR1—Peptide GPCRs—CCR4—malignant glioma	0.00658	0.018	CbGpPWpGaD
Eprosartan—Sweating increased—Temozolomide—malignant glioma	0.00631	0.00994	CcSEcCtD
Eprosartan—Bronchitis—Temozolomide—malignant glioma	0.00623	0.00981	CcSEcCtD
Eprosartan—Hyperglycaemia—Carmustine—malignant glioma	0.00605	0.00952	CcSEcCtD
Eprosartan—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00602	0.00948	CcSEcCtD
Eprosartan—Pollakiuria—Temozolomide—malignant glioma	0.00598	0.00942	CcSEcCtD
Eprosartan—Depression—Carmustine—malignant glioma	0.00596	0.00938	CcSEcCtD
Eprosartan—ABCC2—Irinotecan Pathway—APC—malignant glioma	0.00595	0.0163	CbGpPWpGaD
Eprosartan—CYP2C9—Xenobiotics—CYP2B6—malignant glioma	0.00593	0.0162	CbGpPWpGaD
Eprosartan—Renal failure—Carmustine—malignant glioma	0.00588	0.00925	CcSEcCtD
Eprosartan—Neuropathy peripheral—Carmustine—malignant glioma	0.00586	0.00923	CcSEcCtD
Eprosartan—Hyperglycaemia—Temozolomide—malignant glioma	0.00584	0.0092	CcSEcCtD
Eprosartan—Urinary tract infection—Carmustine—malignant glioma	0.00581	0.00915	CcSEcCtD
Eprosartan—Depression—Temozolomide—malignant glioma	0.00576	0.00907	CcSEcCtD
Eprosartan—Neuropathy peripheral—Temozolomide—malignant glioma	0.00566	0.00892	CcSEcCtD
Eprosartan—Urinary tract infection—Temozolomide—malignant glioma	0.00561	0.00884	CcSEcCtD
Eprosartan—Sinusitis—Temozolomide—malignant glioma	0.00542	0.00853	CcSEcCtD
Eprosartan—Oedema peripheral—Carmustine—malignant glioma	0.00529	0.00832	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—HLA-C—malignant glioma	0.00517	0.0142	CbGpPWpGaD
Eprosartan—Visual impairment—Carmustine—malignant glioma	0.00517	0.00814	CcSEcCtD
Eprosartan—Pharyngitis—Temozolomide—malignant glioma	0.00515	0.0081	CcSEcCtD
Eprosartan—CYP2C9—Xenobiotics—CYP2C18—malignant glioma	0.00514	0.0141	CbGpPWpGaD
Eprosartan—Oedema peripheral—Temozolomide—malignant glioma	0.00511	0.00804	CcSEcCtD
Eprosartan—Visual impairment—Temozolomide—malignant glioma	0.005	0.00787	CcSEcCtD
Eprosartan—AGTR1—Peptide GPCRs—CXCR3—malignant glioma	0.00489	0.0134	CbGpPWpGaD
Eprosartan—AGTR1—Arf6 signaling events—MET—malignant glioma	0.00487	0.0133	CbGpPWpGaD
Eprosartan—Tinnitus—Temozolomide—malignant glioma	0.00483	0.00761	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PTK2—malignant glioma	0.00475	0.013	CbGpPWpGaD
Eprosartan—Chills—Temozolomide—malignant glioma	0.00465	0.00733	CcSEcCtD
Eprosartan—AGTR1—Arf6 signaling events—EGF—malignant glioma	0.00453	0.0124	CbGpPWpGaD
Eprosartan—Back pain—Carmustine—malignant glioma	0.00452	0.00711	CcSEcCtD
Eprosartan—AGTR1—Peptide GPCRs—BDKRB2—malignant glioma	0.00447	0.0123	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—IL12B—malignant glioma	0.0044	0.0121	CbGpPWpGaD
Eprosartan—Tremor—Carmustine—malignant glioma	0.00438	0.00689	CcSEcCtD
Eprosartan—Back pain—Temozolomide—malignant glioma	0.00437	0.00688	CcSEcCtD
Eprosartan—Tremor—Temozolomide—malignant glioma	0.00423	0.00666	CcSEcCtD
Eprosartan—Ill-defined disorder—Temozolomide—malignant glioma	0.00419	0.00659	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—FTH1—malignant glioma	0.00415	0.0114	CbGpPWpGaD
Eprosartan—Angioedema—Temozolomide—malignant glioma	0.00412	0.00649	CcSEcCtD
Eprosartan—Malaise—Temozolomide—malignant glioma	0.00407	0.00641	CcSEcCtD
Eprosartan—CYP2C9—Constitutive Androstane Receptor Pathway—CYP2B6—malignant glioma	0.00407	0.0112	CbGpPWpGaD
Eprosartan—Vertigo—Temozolomide—malignant glioma	0.00406	0.00639	CcSEcCtD
Eprosartan—Palpitations—Temozolomide—malignant glioma	0.00399	0.00628	CcSEcCtD
Eprosartan—Myalgia—Carmustine—malignant glioma	0.00398	0.00626	CcSEcCtD
Eprosartan—Chest pain—Carmustine—malignant glioma	0.00398	0.00626	CcSEcCtD
Eprosartan—Anxiety—Carmustine—malignant glioma	0.00396	0.00624	CcSEcCtD
Eprosartan—Cough—Temozolomide—malignant glioma	0.00394	0.0062	CcSEcCtD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2B6—malignant glioma	0.00388	0.0106	CbGpPWpGaD
Eprosartan—Myalgia—Temozolomide—malignant glioma	0.00384	0.00605	CcSEcCtD
Eprosartan—Arthralgia—Temozolomide—malignant glioma	0.00384	0.00605	CcSEcCtD
Eprosartan—Anxiety—Temozolomide—malignant glioma	0.00383	0.00603	CcSEcCtD
Eprosartan—Discomfort—Temozolomide—malignant glioma	0.0038	0.00598	CcSEcCtD
Eprosartan—Dry mouth—Temozolomide—malignant glioma	0.00376	0.00592	CcSEcCtD
Eprosartan—Thrombocytopenia—Carmustine—malignant glioma	0.00373	0.00588	CcSEcCtD
Eprosartan—Tachycardia—Carmustine—malignant glioma	0.00372	0.00586	CcSEcCtD
Eprosartan—Anorexia—Carmustine—malignant glioma	0.00363	0.00572	CcSEcCtD
Eprosartan—Thrombocytopenia—Temozolomide—malignant glioma	0.00361	0.00568	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—FN1—malignant glioma	0.0036	0.00986	CbGpPWpGaD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—F2—malignant glioma	0.0036	0.00986	CbGpPWpGaD
Eprosartan—Hypotension—Carmustine—malignant glioma	0.00356	0.00561	CcSEcCtD
Eprosartan—Hyperhidrosis—Temozolomide—malignant glioma	0.00356	0.00561	CcSEcCtD
Eprosartan—Anorexia—Temozolomide—malignant glioma	0.00351	0.00553	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Carmustine—malignant glioma	0.00347	0.00547	CcSEcCtD
Eprosartan—Insomnia—Carmustine—malignant glioma	0.00345	0.00543	CcSEcCtD
Eprosartan—Paraesthesia—Carmustine—malignant glioma	0.00342	0.00539	CcSEcCtD
Eprosartan—Dyspnoea—Carmustine—malignant glioma	0.0034	0.00535	CcSEcCtD
Eprosartan—Somnolence—Carmustine—malignant glioma	0.00339	0.00534	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PTPN11—malignant glioma	0.00338	0.00927	CbGpPWpGaD
Eprosartan—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.00336	0.00528	CcSEcCtD
Eprosartan—Insomnia—Temozolomide—malignant glioma	0.00333	0.00525	CcSEcCtD
Eprosartan—Decreased appetite—Carmustine—malignant glioma	0.00331	0.00522	CcSEcCtD
Eprosartan—Paraesthesia—Temozolomide—malignant glioma	0.00331	0.00521	CcSEcCtD
Eprosartan—Dyspnoea—Temozolomide—malignant glioma	0.00328	0.00517	CcSEcCtD
Eprosartan—Somnolence—Temozolomide—malignant glioma	0.00328	0.00516	CcSEcCtD
Eprosartan—Pain—Carmustine—malignant glioma	0.00326	0.00513	CcSEcCtD
Eprosartan—Constipation—Carmustine—malignant glioma	0.00326	0.00513	CcSEcCtD
Eprosartan—Dyspepsia—Temozolomide—malignant glioma	0.00324	0.00511	CcSEcCtD
Eprosartan—Decreased appetite—Temozolomide—malignant glioma	0.0032	0.00504	CcSEcCtD
Eprosartan—Fatigue—Temozolomide—malignant glioma	0.00318	0.005	CcSEcCtD
Eprosartan—Pain—Temozolomide—malignant glioma	0.00315	0.00496	CcSEcCtD
Eprosartan—Constipation—Temozolomide—malignant glioma	0.00315	0.00496	CcSEcCtD
Eprosartan—Feeling abnormal—Carmustine—malignant glioma	0.00314	0.00495	CcSEcCtD
Eprosartan—Gastrointestinal pain—Carmustine—malignant glioma	0.00312	0.00491	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CCR4—malignant glioma	0.00309	0.00848	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—PDGFRA—malignant glioma	0.00308	0.00844	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—HLA-B—malignant glioma	0.00306	0.00839	CbGpPWpGaD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MMP2—malignant glioma	0.00305	0.00837	CbGpPWpGaD
Eprosartan—Feeling abnormal—Temozolomide—malignant glioma	0.00304	0.00478	CcSEcCtD
Eprosartan—Abdominal pain—Carmustine—malignant glioma	0.00301	0.00475	CcSEcCtD
Eprosartan—Body temperature increased—Carmustine—malignant glioma	0.00301	0.00475	CcSEcCtD
Eprosartan—Gastrointestinal pain—Temozolomide—malignant glioma	0.00301	0.00474	CcSEcCtD
Eprosartan—Urticaria—Temozolomide—malignant glioma	0.00293	0.00461	CcSEcCtD
Eprosartan—Body temperature increased—Temozolomide—malignant glioma	0.00291	0.00459	CcSEcCtD
Eprosartan—Abdominal pain—Temozolomide—malignant glioma	0.00291	0.00459	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—FGF2—malignant glioma	0.0029	0.00795	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—HLA-A—malignant glioma	0.00284	0.00777	CbGpPWpGaD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—malignant glioma	0.00283	0.00774	CbGpPWpGaD
Eprosartan—Hypersensitivity—Carmustine—malignant glioma	0.00281	0.00442	CcSEcCtD
Eprosartan—Asthenia—Carmustine—malignant glioma	0.00274	0.00431	CcSEcCtD
Eprosartan—Hypersensitivity—Temozolomide—malignant glioma	0.00271	0.00427	CcSEcCtD
Eprosartan—Asthenia—Temozolomide—malignant glioma	0.00264	0.00416	CcSEcCtD
Eprosartan—Diarrhoea—Carmustine—malignant glioma	0.00261	0.00411	CcSEcCtD
Eprosartan—Pruritus—Temozolomide—malignant glioma	0.00261	0.0041	CcSEcCtD
Eprosartan—Dizziness—Carmustine—malignant glioma	0.00252	0.00397	CcSEcCtD
Eprosartan—Diarrhoea—Temozolomide—malignant glioma	0.00252	0.00397	CcSEcCtD
Eprosartan—AGTR1—Arf6 signaling events—EGFR—malignant glioma	0.00247	0.00676	CbGpPWpGaD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2B6—malignant glioma	0.00246	0.00674	CbGpPWpGaD
Eprosartan—Dizziness—Temozolomide—malignant glioma	0.00244	0.00384	CcSEcCtD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—CYP2B6—malignant glioma	0.00243	0.00666	CbGpPWpGaD
Eprosartan—Vomiting—Carmustine—malignant glioma	0.00242	0.00382	CcSEcCtD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR4—malignant glioma	0.00242	0.00664	CbGpPWpGaD
Eprosartan—Rash—Carmustine—malignant glioma	0.0024	0.00378	CcSEcCtD
Eprosartan—Dermatitis—Carmustine—malignant glioma	0.0024	0.00378	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—CD80—malignant glioma	0.00239	0.00656	CbGpPWpGaD
Eprosartan—Headache—Carmustine—malignant glioma	0.00239	0.00376	CcSEcCtD
Eprosartan—Vomiting—Temozolomide—malignant glioma	0.00234	0.00369	CcSEcCtD
Eprosartan—Rash—Temozolomide—malignant glioma	0.00232	0.00366	CcSEcCtD
Eprosartan—Dermatitis—Temozolomide—malignant glioma	0.00232	0.00365	CcSEcCtD
Eprosartan—Headache—Temozolomide—malignant glioma	0.00231	0.00363	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CXCR3—malignant glioma	0.0023	0.0063	CbGpPWpGaD
Eprosartan—Nausea—Carmustine—malignant glioma	0.00226	0.00357	CcSEcCtD
Eprosartan—Nausea—Temozolomide—malignant glioma	0.00219	0.00345	CcSEcCtD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2C18—malignant glioma	0.00213	0.00585	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—BDKRB2—malignant glioma	0.00213	0.00584	CbGpPWpGaD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—CYP2C18—malignant glioma	0.00211	0.00577	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—BDKRB2—malignant glioma	0.0021	0.00577	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR4—malignant glioma	0.00208	0.00569	CbGpPWpGaD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP2B6—malignant glioma	0.002	0.00547	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—KNG1—malignant glioma	0.00194	0.00531	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—KNG1—malignant glioma	0.00191	0.00525	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—BDKRB2—malignant glioma	0.00191	0.00522	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—IFNG—malignant glioma	0.00189	0.00518	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonic acid metabolism—PTGS1—malignant glioma	0.00187	0.00513	CbGpPWpGaD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR3—malignant glioma	0.0018	0.00494	CbGpPWpGaD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—malignant glioma	0.00177	0.00484	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—CXCL8—malignant glioma	0.00176	0.00482	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—malignant glioma	0.00173	0.00475	CbGpPWpGaD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP2C18—malignant glioma	0.00173	0.00474	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—IL1B—malignant glioma	0.00169	0.00462	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—CASP3—malignant glioma	0.00168	0.00461	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—IL2—malignant glioma	0.00168	0.00461	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—SLC5A5—malignant glioma	0.00166	0.00455	CbGpPWpGaD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—BDKRB2—malignant glioma	0.00165	0.00451	CbGpPWpGaD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—malignant glioma	0.00161	0.00441	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CCR4—malignant glioma	0.00158	0.00433	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—SLC6A3—malignant glioma	0.00158	0.00433	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR3—malignant glioma	0.00154	0.00423	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—malignant glioma	0.00154	0.00421	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—COX8A—malignant glioma	0.00145	0.00399	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—VEGFA—malignant glioma	0.00143	0.00392	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—BDKRB2—malignant glioma	0.00141	0.00387	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—LATS2—malignant glioma	0.00135	0.0037	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—GSTP1—malignant glioma	0.00134	0.00366	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—FTH1—malignant glioma	0.00133	0.00364	CbGpPWpGaD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—malignant glioma	0.00131	0.0036	CbGpPWpGaD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—PTGS1—malignant glioma	0.00131	0.00359	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—KNG1—malignant glioma	0.00128	0.00352	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—F2—malignant glioma	0.00125	0.00343	CbGpPWpGaD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—malignant glioma	0.00124	0.0034	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—F2—malignant glioma	0.00124	0.00339	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—TNF—malignant glioma	0.00122	0.00336	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CXCR3—malignant glioma	0.00117	0.00322	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ATP1B2—malignant glioma	0.00116	0.00319	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—APOD—malignant glioma	0.00113	0.0031	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—F2—malignant glioma	0.00112	0.00307	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—BDKRB2—malignant glioma	0.00107	0.00295	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—CYP2B6—malignant glioma	0.00106	0.0029	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—PDGFB—malignant glioma	0.00106	0.0029	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—malignant glioma	0.00105	0.00289	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP2B6—malignant glioma	0.00105	0.00286	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—LATS1—malignant glioma	0.00102	0.00281	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—KNG1—malignant glioma	0.000978	0.00268	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—CYP2C18—malignant glioma	0.000919	0.00252	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP2C18—malignant glioma	0.000906	0.00248	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CCR4—malignant glioma	0.000893	0.00245	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CXCL8—malignant glioma	0.000872	0.00239	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—malignant glioma	0.000842	0.00231	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—F2—malignant glioma	0.00083	0.00227	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CCR4—malignant glioma	0.000811	0.00222	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTT1—malignant glioma	0.000743	0.00204	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonic acid metabolism—PTGS2—malignant glioma	0.000717	0.00197	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—PTGS1—malignant glioma	0.000696	0.00191	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MDK—malignant glioma	0.000691	0.00189	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CXCR3—malignant glioma	0.000664	0.00182	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—DTX1—malignant glioma	0.00066	0.00181	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—F2—malignant glioma	0.000632	0.00173	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—BDKRB2—malignant glioma	0.000607	0.00166	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CXCR3—malignant glioma	0.000603	0.00165	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—malignant glioma	0.000585	0.0016	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—TFRC—malignant glioma	0.000579	0.00159	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—malignant glioma	0.000577	0.00158	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—PIK3CA—malignant glioma	0.00056	0.00154	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—KNG1—malignant glioma	0.000552	0.00151	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—BDKRB2—malignant glioma	0.000551	0.00151	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—malignant glioma	0.000545	0.00149	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC5A5—malignant glioma	0.000532	0.00146	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SUFU—malignant glioma	0.000524	0.00144	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—RTEL1—malignant glioma	0.000521	0.00143	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HEY2—malignant glioma	0.000518	0.00142	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTP1—malignant glioma	0.000515	0.00141	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTP1—malignant glioma	0.000508	0.00139	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC6A3—malignant glioma	0.000506	0.00139	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GFAP—malignant glioma	0.000506	0.00139	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—KNG1—malignant glioma	0.000502	0.00138	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—malignant glioma	0.000501	0.00137	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SPHK1—malignant glioma	0.000489	0.00134	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HEY1—malignant glioma	0.000479	0.00131	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCR4—malignant glioma	0.000479	0.00131	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HIST1H3B—malignant glioma	0.000466	0.00128	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CXCL8—malignant glioma	0.000445	0.00122	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—MMP3—malignant glioma	0.000445	0.00122	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—JAG2—malignant glioma	0.000425	0.00116	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—malignant glioma	0.000372	0.00102	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—SPHK1—malignant glioma	0.00036	0.000987	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—H3F3A—malignant glioma	0.00036	0.000986	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—F2—malignant glioma	0.000357	0.000979	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCR3—malignant glioma	0.000356	0.000976	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—YWHAE—malignant glioma	0.000346	0.00095	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NTRK2—malignant glioma	0.000346	0.00095	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FLT1—malignant glioma	0.000345	0.000945	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—DUSP6—malignant glioma	0.000343	0.000941	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CG—malignant glioma	0.000342	0.000937	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—JAG1—malignant glioma	0.000339	0.000929	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOTCH3—malignant glioma	0.000338	0.000925	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FBXW7—malignant glioma	0.000332	0.00091	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—BDKRB2—malignant glioma	0.000326	0.000893	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—F2—malignant glioma	0.000324	0.000889	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—AKT2—malignant glioma	0.000313	0.000857	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CG—malignant glioma	0.00031	0.000851	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PTPN11—malignant glioma	0.000305	0.000836	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOTCH2—malignant glioma	0.000303	0.00083	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CD—malignant glioma	0.0003	0.000823	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—COX8A—malignant glioma	0.000299	0.00082	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KNG1—malignant glioma	0.000296	0.000812	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—AKT2—malignant glioma	0.000284	0.000778	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NTRK1—malignant glioma	0.000282	0.000774	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CD—malignant glioma	0.000273	0.000748	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—malignant glioma	0.000267	0.000733	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MMP3—malignant glioma	0.000263	0.00072	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CB—malignant glioma	0.000262	0.000718	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CDKN2B—malignant glioma	0.00026	0.000713	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ASMT—malignant glioma	0.000254	0.000697	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTK2—malignant glioma	0.000253	0.000693	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CXCL8—malignant glioma	0.000252	0.00069	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—malignant glioma	0.000249	0.000681	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HES1—malignant glioma	0.000248	0.000681	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NCOR1—malignant glioma	0.000247	0.000677	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—RAF1—malignant glioma	0.000244	0.000668	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—IL2—malignant glioma	0.00024	0.000659	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—BCAN—malignant glioma	0.000239	0.000655	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CB—malignant glioma	0.000238	0.000652	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PDGFRA—malignant glioma	0.000236	0.000648	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SPP1—malignant glioma	0.00023	0.000629	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—RAF1—malignant glioma	0.000229	0.000628	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CXCL8—malignant glioma	0.000229	0.000626	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL2—malignant glioma	0.000218	0.000599	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TERT—malignant glioma	0.000218	0.000596	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PDGFB—malignant glioma	0.000212	0.000582	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FGFR1—malignant glioma	0.000211	0.000579	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HIF1A—malignant glioma	0.000208	0.00057	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CAV1—malignant glioma	0.000201	0.000552	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KDR—malignant glioma	0.000199	0.000545	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—IDH2—malignant glioma	0.000193	0.000528	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—F2—malignant glioma	0.000192	0.000525	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FN1—malignant glioma	0.000192	0.000525	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—BAD—malignant glioma	0.000189	0.000519	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOTCH1—malignant glioma	0.000187	0.000514	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CD80—malignant glioma	0.000184	0.000503	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APC—malignant glioma	0.000183	0.000502	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CG—malignant glioma	0.000183	0.000502	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	0.000182	0.000498	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP2B6—malignant glioma	0.000181	0.000497	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EGF—malignant glioma	0.000181	0.000497	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTPN11—malignant glioma	0.00018	0.000494	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—BRAF—malignant glioma	0.000172	0.000472	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AKT2—malignant glioma	0.000168	0.00046	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—EGFR—malignant glioma	0.000167	0.000458	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—IDH1—malignant glioma	0.000166	0.000454	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CD—malignant glioma	0.000161	0.000442	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SPHK1—malignant glioma	0.00016	0.00044	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CA—malignant glioma	0.00016	0.000437	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—KRAS—malignant glioma	0.000158	0.000432	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP2C18—malignant glioma	0.000157	0.000431	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FGF2—malignant glioma	0.000154	0.000423	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	0.000148	0.000406	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CA—malignant glioma	0.000145	0.000397	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MDM2—malignant glioma	0.000144	0.000396	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RAF1—malignant glioma	0.000144	0.000394	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ERBB2—malignant glioma	0.000142	0.00039	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CB—malignant glioma	0.00014	0.000385	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCL8—malignant glioma	0.000135	0.00037	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	0.000135	0.00037	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—AKT1—malignant glioma	0.00013	0.000357	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	0.00013	0.000357	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CASP3—malignant glioma	0.000129	0.000354	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL2—malignant glioma	0.000129	0.000354	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTT1—malignant glioma	0.000127	0.000348	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MMP9—malignant glioma	0.000122	0.000335	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTEN—malignant glioma	0.000121	0.000333	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTGS1—malignant glioma	0.000119	0.000326	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	0.000119	0.000325	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—AKT1—malignant glioma	0.000118	0.000325	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—BCHE—malignant glioma	0.000111	0.000303	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—VEGFA—malignant glioma	0.00011	0.0003	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLC5A5—malignant glioma	0.000109	0.0003	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—STAT3—malignant glioma	0.000109	0.000298	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	0.000103	0.000283	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	0.000102	0.000281	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MYC—malignant glioma	0.000101	0.000276	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EGFR—malignant glioma	9.87e-05	0.00027	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KRAS—malignant glioma	9.32e-05	0.000255	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	8.94e-05	0.000245	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTP1—malignant glioma	8.81e-05	0.000241	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CAT—malignant glioma	8.57e-05	0.000235	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CA—malignant glioma	8.56e-05	0.000235	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TP53—malignant glioma	8.28e-05	0.000227	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NCOR1—malignant glioma	8.1e-05	0.000222	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AKT1—malignant glioma	7e-05	0.000192	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CAV1—malignant glioma	6.6e-05	0.000181	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	6.3e-05	0.000173	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CG—malignant glioma	6.01e-05	0.000165	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PPARG—malignant glioma	5.8e-05	0.000159	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CD—malignant glioma	5.28e-05	0.000145	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CB—malignant glioma	4.61e-05	0.000126	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTGS2—malignant glioma	4.56e-05	0.000125	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTEN—malignant glioma	3.98e-05	0.000109	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CA—malignant glioma	2.81e-05	7.7e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—AKT1—malignant glioma	2.29e-05	6.29e-05	CbGpPWpGaD
